2020 April 21, 2020
CD-19 Antibody Making Waves at JPM2020
1 min read
A next generation CD-19 mAb, tafasitamab is all the buzz at JPM2020! Incyte acquired tafasitamab from Morphosys, who had been developing the drug under the code name MOR00208 (see link below). While the pipeline for targeting CD-19 has been overwhelmingly CAR-T, tafasitamab is leading the way for increased investment in CD-19 antibodies! Kognitic‘s platform enhances big pharma portfolio strategies by giving access to real-time data of all target landscapes. View the image below to see who is driving the CD-19 antibody pipeline!
https://www.evaluate.com/vantage/articles/analysis/why-2020-spotlight-will-fall-tafasitamab